EML4-ALK in non-small-cell lung cancer: the breathtaking progress from benchtop to Phase III clinical trial

Author： Ku Geoffrey Y   Lima Jopes Jr Gilberto de  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.8, Iss.1, 2011-01, pp. : 55-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidemiology of EML4–ALK translocations in a small, German non-small-cell lung cancer patient cohort

By Schildgen Verena   Lochi Vincenza   Lüsebrink Jessica   Brockmann Michael   Schildgen Oliver  

Personalized Medicine, Vol. 9, Iss. 8, 2012-11 ,pp. : 801-803

Future Medicine

Access to resources Recommend Favorite

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite

Clinical Phase II Trial of Treosulfan in Patients with Non-Resectable Non-Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 316-319

Karger

Access to resources Recommend Favorite

Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and Vinorelbine

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 35-41

Karger

Access to resources Recommend Favorite

Phase II Trial of Weekly Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 224-228

Karger

Access to resources Recommend Favorite